Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-1345 + mRNA-1273.214
- Development stage
- Unknown
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
mRNA-1345 + mRNA-1273.214 refers to the coadministration of two separate mRNA vaccines developed by Moderna: mRNA-1345 (mRESVIA) and mRNA-1273.214 (Spikevax Bivalent Original/Omicron BA.1). mRNA-1345 is a monovalent vaccine encoding the pre-fusion F glycoprotein of the respiratory syncytial virus (RSV). mRNA-1273.214 is a bivalent COVID-19 vaccine containing 25 μg each of mRNA encoding the spike protein of the ancestral SARS-CoV-2 strain (Wuhan-Hu-1) and the Omicron BA.1 variant. This combination was evaluated in a Phase 3 clinical trial (NCT05330975) for simultaneous administration in adults aged 50 years and older, demonstrating that coadministration is safe and elicits immune responses non-inferior to those of the vaccines administered individually.
- Brand names
- mRESVIASpikevax Bivalent Original/Omicron BA.1
- Other names
- mRNA-1345 and mRNA-1273.214 coadministrationmRNA1345 and mRNA-1273.214 coadministrationmRNA 1345 and mRNA-1273.214 coadministrationRSV vaccine + COVID-19 vaccine
02
Targets
SARS-CoV-2 spikeRSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on mRNA-1345 + mRNA-1273.214.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-1345 + mRNA-1273.214.